Review article: Description and management of fatigue in inflammatory bowel disease. 2013

W Czuber-Dochan, and E Ream, and C Norton
King's College London, Florence Nightingale School of Nursing & Midwifery, London, UK. wladzia.czuber-dochan@kcl.ac.uk

BACKGROUND Fatigue is a common and leading concern for patients with inflammatory bowel disease (IBD). It is managed inadequately in IBD, and there is little evidence to support interventions. OBJECTIVE To examine patients' experience of and factors contributing to IBD-fatigue, and to appraise its management by patients and healthcare professionals. METHODS Seven electronic databases were searched. Subject headings and free-text searching were used, with no time limit set. Reference lists of retrieved papers were searched manually. RESULTS Twenty-eight papers were reviewed. Researchers used terms including 'fatigue', 'low energy', 'tiredness', 'decline in vitality and vigour' and 'reduced energy and vitality'. Different definitions were used to conceptualise fatigue. None of the reviewed studies asked patients to describe the experience of fatigue in their own words. Numerous physical, psychological and situational factors associated with fatigue were identified. Three small randomised control trials reported a favourable effect of infliximab and adalimumab on fatigue. One intervention study reported benefit from a stress management programme and one from solution-focused therapy. CONCLUSIONS Inconsistent use of terminology, lack of data from patients' perspective on inflammatory bowel disease-fatigue and lack of evidence to support its management contribute to fatigue being largely ignored or overlooked by healthcare professionals. Future research should explore the experience of IBD-fatigue from the individual patient perspective. Further studies are required to fully explore the factors associated with fatigue and to develop patient-centred interventions to reduce fatigue.

UI MeSH Term Description Entries
D012064 Relaxation Therapy Treatment to improve one's health condition by using techniques that can reduce PHYSIOLOGICAL STRESS; PSYCHOLOGICAL STRESS; or both. Relaxation Techniques,Therapeutic Relaxation,Ecotherapy,Nature Therapy,Relaxation Technics,Therapy, Relaxation,Ecotherapies,Nature Therapies,Relaxation Technic,Relaxation Technique,Relaxation, Therapeutic,Technic, Relaxation,Technique, Relaxation,Techniques, Relaxation,Therapy, Nature
D005221 Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. Lassitude
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068879 Adalimumab A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. Adalimumab-adbm,Adalimumab-atto,Amjevita,Cyltezo,D2E7 Antibody,Humira,Antibody, D2E7
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015212 Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. Bowel Diseases, Inflammatory,Inflammatory Bowel Disease
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

W Czuber-Dochan, and E Ream, and C Norton
August 2021, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
November 1998, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
December 2007, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
May 2004, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
April 2015, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
September 2006, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
October 2004, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
October 2004, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
July 2005, Alimentary pharmacology & therapeutics,
W Czuber-Dochan, and E Ream, and C Norton
July 2010, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!